Onco Actu du 25 novembre 2016

	1. Biologie
Cancer cells hijack healthy cells to regrow after treatment [Cancer Research UK] “This adds to the growing evidence that cancer drugs can affect normal cells that are found within and around tumours. And these effects can make treatments less effective in the long run.”
Lung cancer cells spread like unanchored tents, study says [BBC News] Writing in the Journal of Clinical Investigation, researchers from York and the University of Texas describe how the communications centre of a cell - known as the Golgi apparatus - receives a signal from proteins which prompts the movement of membrane sacks inside it.
	2. Etiologie
Jet lag and liver cancer – what’s the story? [Cancer Research UK] For their study, the team disrupted the circadian rhythm of mice in the lab by changing their exposure to light over prolonged periods, thus disrupting their sleeping patterns.
	3.2 Prévention - Obésité
The obesity epidemic is an economic issue [The Guardian] Free-market forces have helped create a health crisis – and governments must take action to stop subsidising junk food.
	5. Traitements
Rewiring cancers’ circuits – a new way to kil? [Cancer Research UK] HIF-1 helps tumours grow new blood vessels, which the cells need to grow and survive. And the new study, led by Professor Ali Tavassoli, reveals a potential new way to cut off this blood supply by targeting HIF-1.
ESC Position Paper on Anticancer Treatments and Cardiovascular Toxicity [ESMO] The paper covers all aspects of cardiovascular toxicity in the context of anticancer treatment, providing expert opinion for management and summarising the most important recommendations.
	5.12.2 Immunothérapies - CAR-T
Latest deaths in Juno trial underscore the need for greater transparency in clinical trials [STAT] We don’t know exactly what the FDA did or did not do because all of this regulatory activity happens outside public view. The existence of an IND, the details of a clinical hold, and the rationale for removing the hold are deemed trade secrets that the FDA is not allowed to routinely disclose.
	5.2 Pharma
NINLAROTM （ixazomib） Receives Conditional Approval from the European Commission to Treat Multiple Myeloma [Takeda] Approval Based on TOURMALINE-MM1 Study Results, Which Demonstrated Statistically Significant Six-Month Improvement in Progression-Free Survival.
	5.3 Traitements - FDA, EMA, NICE...
Clinical data for two more medicines now available online [EMA] Armisarte is a hybrid product, meaning it is similar to its reference product but is available in a different pharmaceutical form. It is indicated for the treatment of malignant pleural mesothelioma lung cancer and advanced non-small-cell lung cancer.
	5.4 Traitements - Economie
Janssen drops price of Imbruvica to secure NICE nod [Pharma Times] A year's treatment costs more than £55,000 per patient, but the NHS will pay less than this as per the confidential price cut.
Insider interview: Roche discusses efficacy of CDF and NICE [Pharmafile] I think they’re going to struggle with capacity and I think they’re going to struggle to schedule things in in a timely fashion.
NICE reverses decision on CDF leukaemia drug after price drop [NICE] An earlier recommendation by NICE did not recommend ibrutinib, also known as Imbruvica, for routine NHS use. However, following a reduction in price, the independent appraisal committee were able to approve the drug as cost effective.
Costly leukemia pill wins UK green light after price cut [Reuters] The move comes as NICE reappraises all drugs covered by the Cancer Drugs Fund (CDF), which was overhauled earlier this year.
	6. Lutte contre les cancers
What does it take to be a leader in precision medicine? [STAT] Creating and bringing together robust clinical decision support tools will not make a difference if physicians refuse to use them. A great precision medicine leader, therefore, must be a health care innovator and an evangelist to patients and the clinical community.
	6.1 Observation
Mouth cancer rates soar over 20 years [Cancer Research UK] The figures – released during Mouth Cancer Action Month – reveal the cancer is on the rise for men and women, young and old, climbing from eight to 13 cases per 100,000 people over the last two decades.
	6.11 Patients
Living With Cancer: The Gift of Grace [NY Times] An email I received from a reader some time ago has begun to haunt me. The reader’s sister was dying of cancer. How, she asked me, would I respond to the word “grace” in the context of a cancer death?
	6.6 Publications
Why research papers have so many authors [The Economist] One thing that determines how quickly a researcher climbs the academic ladder is his publication record. The quality of this clearly matters—but so does its quantity.
	6.7 DMP, Big Data & applis
Google’s DeepMind agrees new deal to share NHS patient data [New Scientist] The Streams app is designed to deliver an alert about a patient’s condition to a doctor’s or nurse’s cellphone in a similar way to getting a news notification. It will initially be used from 2017 to spot people at risk of kidney problems, but is due to be expanded over the five years to include other functions such as detecting blood poisoning and coordinating patient treatment.
	6.7.1 Bioinformatique
Tricky gene mutations detected by new easy-to-use DECoN software [Institute of Cancer Research] The software, called DECoN, accurately and quickly detects changes in copy number of blocks of DNA called exons, by analysing sequencing data already generated to identify smaller gene changes.